{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T16:45:12Z","timestamp":1784306712733,"version":"3.55.0"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2018,5,14]],"date-time":"2018-05-14T00:00:00Z","timestamp":1526256000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,8,1]]},"DOI":"10.1093\/ijnp\/pyy045","type":"journal-article","created":{"date-parts":[[2018,5,12]],"date-time":"2018-05-12T11:08:52Z","timestamp":1526123332000},"page":"748-757","source":"Crossref","is-referenced-by-count":28,"title":["Anti-Dementia Drugs for Psychopathology and Cognitive Impairment in Schizophrenia: A Systematic Review and Meta-Analysis"],"prefix":"10.1093","volume":"21","author":[{"given":"Taro","family":"Kishi","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Fujita Health University School of Medicine, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshikazu","family":"Ikuta","sequence":"additional","affiliation":[{"name":"Department of Communication Sciences and Disorders, School of Applied Sciences, University of Mississippi, MS USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuto","family":"Oya","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Fujita Health University School of Medicine, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Matsunaga","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Fujita Health University School of Medicine, Aichi, Japan"},{"name":"Department of Department of Geriatrics and Cognitive Disorders, Fujita Health University School of Medicine, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Matsuda","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Jikei University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nakao","family":"Iwata","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Fujita Health University School of Medicine, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,5,14]]},"reference":[{"key":"key\n\t\t\t\t20180801050943_CIT0001","unstructured":"Allen T , McEvoyJ, KeefeR(2003)Galantamine as an adjunctive therapy in the treatment of schizophrenia. Paper presented at: 11th Congress of the International Psychogeriatric Association (IPA); August 17\u201322, 2003; Chicago, IL."},{"key":"key\n\t\t\t\t20180801050943_CIT0002","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1001\/archpsyc.1982.04290070020005","article-title":"Negative symptoms in schizophrenia. Definition and reliability","volume":"39","author":"Andreasen","year":"1982","journal-title":"Arch Gen Psychiatry"},{"key":"key\n\t\t\t\t20180801050943_CIT0003","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/schbul\/22.1.5","article-title":"Cognitive impairment in elderly schizophrenia: a dementia (still) lacking distinctive histopathology","volume":"22","author":"Arnold","year":"1996","journal-title":"Schizophr Bull"},{"key":"key\n\t\t\t\t20180801050943_CIT0004","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/JCP.0000000000000720","article-title":"A randomized clinical trial of oxytocin or galantamine for the treatment of negative symptoms and cognitive impairments in people with schizophrenia","volume":"37","author":"Buchanan","year":"2017","journal-title":"J Clin Psychopharmacol"},{"key":"key\n\t\t\t\t20180801050943_CIT0005","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1192\/bjp.bp.111.107359","article-title":"Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: meta-analytical investigation of efficacy","volume":"203","author":"Choi","year":"2013","journal-title":"Br J Psychiatry"},{"key":"key\n\t\t\t\t20180801050943_CIT0006","volume-title":"Review Manager (RevMan) [computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre","author":"Collaboration TC","year":"2014"},{"key":"key\n\t\t\t\t20180801050943_CIT0007","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1001\/jamapsychiatry.2017.0624","article-title":"Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence","volume":"74","author":"Correll","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"key\n\t\t\t\t20180801050943_CIT0008","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.4088\/JCP.08m04935gry","article-title":"Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine","volume":"70","author":"de Lucena","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"key\n\t\t\t\t20180801050943_CIT0009","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/01.wnf.0000173714.61744.e6","article-title":"Efficacy and tolerability of low-dose donepezil in schizophrenia","volume":"28","author":"Erickson","year":"2005","journal-title":"Clin Neuropharmacol"},{"key":"key\n\t\t\t\t20180801050943_CIT0010","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1038\/sj.npp.1301391","article-title":"The clinical relevance of percentage improvements on the PANSS score","volume":"32","author":"Fleischhacker","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"key\n\t\t\t\t20180801050943_CIT0011","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"Psychiatry Res"},{"key":"key\n\t\t\t\t20180801050943_CIT0012","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0006-3223(01)01342-7","article-title":"A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia","volume":"51","author":"Friedman","year":"2002","journal-title":"Biol Psychiatry"},{"key":"key\n\t\t\t\t20180801050943_CIT0013","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.biopsych.2004.06.023","article-title":"Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria","volume":"56","author":"Green","year":"2004","journal-title":"Biol Psychiatry"},{"key":"key\n\t\t\t\t20180801050943_CIT0014","volume-title":"Manual for the ECDEU assessment battery","author":"Guy","year":"1970","edition":"2nd ed"},{"key":"key\n\t\t\t\t20180801050943_CIT0015","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/HRP.0000000000000092","article-title":"The longitudinal course of schizophrenia across the lifespan: clinical, cognitive, and neurobiological aspects","volume":"24","author":"Heilbronner","year":"2016","journal-title":"Harv Rev Psychiatry"},{"key":"key\n\t\t\t\t20180801050943_CIT0016","author":"Higgins","year":"2011"},{"key":"key\n\t\t\t\t20180801050943_CIT0017","unstructured":"Hussain M , ChaudhryZ(2003)Rivastigmine and galantamine treatment for schizophrenic cognitive impairment. Paper presented at: The 156th Annual Meeting of the American Psychiatric Association; May 17\u201322, 2003; San Francisco, CA."},{"key":"key\n\t\t\t\t20180801050943_CIT0018","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/mp.2015.68","article-title":"Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials","volume":"20","author":"Iwata","year":"2015","journal-title":"Mol Psychiatry"},{"key":"key\n\t\t\t\t20180801050943_CIT0019","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1192\/S0007125000291514","article-title":"The Positive and negative syndrome scale (PANSS): rationale and standardisation","author":"Kay","year":"1989","journal-title":"Br J Psychiatry"},{"key":"key\n\t\t\t\t20180801050943_CIT0020","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/sj.npp.1301499","article-title":"Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo\/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial","volume":"33","author":"Keefe","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"key\n\t\t\t\t20180801050943_CIT0021","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1007\/s00213-017-4616-7","article-title":"Memantine add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: a meta-analysis","volume":"234","author":"Kishi","year":"2017","journal-title":"Psychopharmacology (Berl)"},{"key":"key\n\t\t\t\t20180801050943_CIT0022","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ajp.2017.02.009","article-title":"Functional near infra-red spectroscopy (fNIRS) in schizophrenia: a review","volume":"27","author":"Kumar","year":"2017","journal-title":"Asian J Psychiatr"},{"key":"key\n\t\t\t\t20180801050943_CIT0023","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/acps.12030","article-title":"Psychopathological long-term outcome of schizophrenia \u2013 a review","volume":"127","author":"Lang","year":"2013","journal-title":"Acta Psychiatr Scand"},{"key":"key\n\t\t\t\t20180801050943_CIT0024","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJM199708213370806","article-title":"Discrepancies between meta-analyses and subsequent large randomized, controlled trials","volume":"337","author":"LeLorier","year":"1997","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180801050943_CIT0025","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180801050943_CIT0026","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/npp.2008.200","article-title":"A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia","volume":"34","author":"Lieberman","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"key\n\t\t\t\t20180801050943_CIT0027","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1017\/S1041610205003017","article-title":"Donepezil for negative signs in elderly patients with schizophrenia: an add-on, double-blind, crossover, placebo-controlled study","volume":"18","author":"Mazeh","year":"2006","journal-title":"Int Psychogeriatr"},{"key":"key\n\t\t\t\t20180801050943_CIT0028","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/mp.2012.47","article-title":"Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents","volume":"17","author":"Miyamoto","year":"2012","journal-title":"Mol Psychiatry"},{"key":"key\n\t\t\t\t20180801050943_CIT0029","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"Bmj"},{"key":"key\n\t\t\t\t20180801050943_CIT0030","doi-asserted-by":"crossref","first-page":"g5741","DOI":"10.1136\/bmj.g5741","article-title":"Industry sponsorship bias in research findings: a network meta-analysis of LDL cholesterol reduction in randomised trials of statins","volume":"349","author":"Naci","year":"2014","journal-title":"Bmj"},{"key":"key\n\t\t\t\t20180801050943_CIT0031","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/acps.12374","article-title":"Second-generation antipsychotic effect on cognition in patients with schizophrenia\u2013a meta-analysis of randomized clinical trials","volume":"131","author":"Nielsen","year":"2015","journal-title":"Acta Psychiatr Scand"},{"key":"key\n\t\t\t\t20180801050943_CIT0032","first-page":"108","article-title":"The effect of add-on memantine on positive, negative and depressive symptoms of schizophrenia: a doubleblind, randomized, controlled trial","volume":"45","author":"Omranifard","year":"2017","journal-title":"Actas Esp Psiquiatr"},{"key":"key\n\t\t\t\t20180801050943_CIT0033","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychol Rep"},{"key":"key\n\t\t\t\t20180801050943_CIT0034","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s12640-013-9398-z","article-title":"Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer\u2019s disease","volume":"24","author":"Parsons","year":"2013","journal-title":"Neurotox Res"},{"key":"key\n\t\t\t\t20180801050943_CIT0035","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2165\/11530260-000000000-00000","article-title":"Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature","volume":"24","author":"Ribeiz","year":"2010","journal-title":"CNS Drugs"},{"key":"key\n\t\t\t\t20180801050943_CIT0036","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.schres.2008.05.004","article-title":"Effects of galantamine on cognitive deficits in smokers and non-smokers with schizophrenia","volume":"103","author":"Sacco","year":"2008","journal-title":"Schizophr Res"},{"key":"key\n\t\t\t\t20180801050943_CIT0037","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/BF02244983","article-title":"Neuronal mechanisms of the attentional dysfunctions in senile dementia and schizophrenia: two sides of the same coin","volume":"114","author":"Sarter","year":"1994","journal-title":"Psychopharmacology (Berl)"},{"key":"key\n\t\t\t\t20180801050943_CIT0038","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(15)01124-1","article-title":"Alzheimer\u2019s disease","volume":"388","author":"Scheltens","year":"2016","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180801050943_CIT0039","first-page":"CD007967","article-title":"Acetylcholinesterase inhibitors for schizophrenia","volume":"1","author":"Singh","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t20180801050943_CIT0040","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0895-4356(00)00242-0","article-title":"Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature","volume":"53","author":"Sterne","year":"2000","journal-title":"J Clin Epidemiol"},{"key":"key\n\t\t\t\t20180801050943_CIT0041","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/npp.2015.162","article-title":"Memantine effects on sensorimotor gating and mismatch negativity in patients with chronic psychosis","volume":"41","author":"Swerdlow","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"key\n\t\t\t\t20180801050943_CIT0042","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(09)60995-8","article-title":"Schizophrenia","volume":"374","author":"van Os","year":"2009","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180801050943_CIT0043","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1192\/bjp.bp.108.057034","article-title":"Frontotemporal dementia presenting as schizophrenia-like psychosis in young people: clinicopathological series and review of cases","volume":"194","author":"Velakoulis","year":"2009","journal-title":"Br J Psychiatry"},{"key":"key\n\t\t\t\t20180801050943_CIT0044","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1517\/13543784.16.12.1987","article-title":"An update on the pharmacology of galantamine","volume":"16","author":"Villarroya","year":"2007","journal-title":"Expert Opin Investig Drugs"}],"container-title":["International Journal of Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ijnp\/article-pdf\/21\/8\/748\/25368855\/pyy045.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T23:39:10Z","timestamp":1571355550000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijnp\/article\/21\/8\/748\/4995713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,14]]},"references-count":44,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,5,14]]},"published-print":{"date-parts":[[2018,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ijnp\/pyy045","relation":{},"ISSN":["1461-1457","1469-5111"],"issn-type":[{"value":"1461-1457","type":"print"},{"value":"1469-5111","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,8]]},"published":{"date-parts":[[2018,5,14]]}}}